Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures

Liver International - Tập 26 Số 7 - Trang 856-863 - 2006
Shira Zelber‐Sagi1,2, Dorit Nitzan3,2, Zamir Halpern1,2, Ran Oren1,2
1The Liver Unit, Department of Gastroenterology, Tel Aviv, Sourasky Medical Center, Tel-Aviv, Israel,
2The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3The Food and Nutrition Administration, Israel Ministry of Health, Tel Aviv, Israel

Tóm tắt

Abstract: Background/Aims: Only a few studies have assessed the epidemiology of non‐alcoholic fatty liver disease (NAFLD). The aim was to evaluate the prevalence of primary NAFLD in a population‐based study in Israel and to determine independent risk factors.Methods: A cross‐sectional study of a subsample of the Israeli national health survey (n=352). Individuals with a known etiology for secondary NAFLD were excluded. Each participant underwent an abdominal ultrasound, biochemical tests and an anthropometric evaluation.Results: Three hundred and twenty‐six subjects (53.4% male, mean age 50.5±10.3 standard deviaton [SD]) met the inclusion criteria. The prevalence of primary NAFLD was 30% (25–35% 95% confidence intervals [CI]). NAFLD was more prevalent in men than women (38% vs. 21%; P=0.001). Compared with ultrasonography, the sensitivity of serum alanine transaminase (ALT) for the diagnosis of primary NAFLD was 8.2%. Risk factors independently associated with NAFLD included male gender (odds ratios (OR)=2.8, 95% CI 1.5–5.3), abdominal obesity (OR=2.9, 95% CI 1.3–6.4), homeostasis model assessment (OR=5.8, 95% CI 2.0–17.2), hyperinsulinemia (OR=2.3, 95% CI 1.2–4.3, P=0.01) and hypertriglyceridemia (OR=2.4, 95% CI 1.3–4.5).Conclusions: NAFLD is prevalent in the general Israeli population and closely related to the metabolic syndrome. The use of ALT as a marker for NAFLD seriously underestimates its prevalence.

Từ khóa


Tài liệu tham khảo

Matteoni C A, 1999, Nonalcoholic fatty liver disease, a spectrum of clinical and pathological severity, 116, 1413

10.1002/hep.20701

Neuschwander‐Tetri B A, 2003, Nonalcoholic steatohepatitis, summary of an AASLD single topic conference, 37, 1202

10.1053/gast.2002.36572

Bedogni G, 2004, Fatty liver, how frequent is it and why?, 3, 63

10.7326/0003-4819-132-2-200001180-00004

10.1055/s-2001-12926

10.3109/00365527709181339

10.3109/00365528609034632

10.1016/0016-5085(95)90724-6

Bedogni G, 2005, Prevalence of and risk factors for nonalcoholic fatty liver disease, the Dionysos nutrition and liver study, 42, 44

10.1016/j.jhep.2005.02.042

Browning J D, 2004, Prevalence of hepatic steatosis in an urban population in the United States, impact of ethnicity, 40, 1387

Marchesini G, 2001, Nonalcoholic fatty liver disease, a feature of the metabolic syndrome, 50, 1844

10.1055/s-2004-823098

10.1016/S0140-6736(05)66378-7

10.1210/jcem.84.5.5661

10.1016/S0002-9343(99)00271-5

10.1053/jhep.2003.50161

Pagano G, 2002, Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome, further evidence for an etiologic association, 35, 367

Nitzan KaluskiD GoldsmithR ChinitzA Ben Arie‐MagledO MayerC GreenM.First National Health and Nutrition Survey Part 2 1999–2001: Israel Center for Disease Control; October 2004. Report No.: Publication 218.

10.1056/NEJMra011775

10.1016/S0016-5085(00)70364-7

Bonora E, 2000, Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity, studies in subjects with various degrees of glucose tolerance and insulin sensitivity, 23, 57

Kuczmarski R J, 2000, Criteria for definition of overweight in transition, background and recommendations for the United States, 72, 1074

10.1056/NEJM199908053410607

Keinan‐Boker L, 2005, Overweight and obesity prevalence in Israel, findings of the first national health and nutrition survey (MABAT), 7, 219

Bacon B R, 1994, Nonalcoholic steatohepatitis, an expanded clinical entity, 107, 1103

Powell E E, 1990, The natural history of nonalcoholic steatohepatitis, a follow-up study of forty-two patients for up to 21 years, 11, 74

Ludwig J, 1980, Nonalcoholic steatohepatitis, Mayo Clinic experiences with a hitherto unnamed disease, 55, 434

Clark J M, 2003, Defining nonalcoholic fatty liver disease, implications for epidemiologic studies, 124, 248

10.7326/0003-4819-137-1-200207020-00006

Joy D, 2003, Diagnosis of fatty liver disease, is biopsy necessary?, 15, 539

10.1259/0007-1285-53-629-440

10.1136/bmj.292.6512.13

10.1016/S0895-4356(01)00355-9

10.2337/diabetes.47.5.699

10.1080/00365520410006431

10.1053/gast.2002.35354

Thông tin
Thông tin xuất bản

Liver International

Tập 26 Số 7

856-863

Thông tin tác giả